{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:25Z","timestamp":1793885725515,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5U54GM104942-08"],"award-info":[{"award-number":["5U54GM104942-08"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.07.039","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:49:23Z","timestamp":1785912563000},"page":"1426.e1-1426.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-2617","authenticated-orcid":false,"given":"Danielle","family":"DeCicco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1549-7921","authenticated-orcid":false,"given":"Sanjana","family":"Nethagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3483-0254","authenticated-orcid":false,"given":"Shanawar","family":"Waris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Ud Din","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-4802","authenticated-orcid":false,"given":"Aaron","family":"Cumpston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-343X","authenticated-orcid":false,"given":"Konstantinos","family":"Sdrimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jtct.2026.07.039_bib0001","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.07.039_bib0002","doi-asserted-by":"crossref","unstructured":"Sharp J, Strati P, Bhatta S, et al. Real-world outcomes and toxicities of CAR-T in relapsed\/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. doi:10.1182\/bloodadvances.2025019115","DOI":"10.1182\/bloodadvances.2025019115"},{"key":"10.1016\/j.jtct.2026.07.039_bib0003","doi-asserted-by":"crossref","unstructured":"Shadman M, LeBlanc M, Rimsza L, et al. Treatment of follicular lymphoma with CHOP and anti-CD20 therapy: 15-year follow-up of the SWOG S0016 trial. JAMA Oncol. doi:10.1001\/jamaoncol.2026.0042","DOI":"10.1001\/jamaoncol.2026.0042"},{"key":"10.1016\/j.jtct.2026.07.039_bib0004","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, et al. Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma. J Clin Oncol. doi:10.1200\/JCO-25-00668","DOI":"10.1200\/JCO-25-00668"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.039_bib0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.039_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.039_bib0007","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas. 2026. https:\/\/www.nccn.org (Accessed March 3, 2026)"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.039_bib0008","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: a review of pharmacology, clinical use and immunological effects","volume":"47","author":"Lalic","year":"2022","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.039_bib0009","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00277-026-06770-2","article-title":"Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (>70 y) with follicular lymphoma: a tertiary academic center experience","volume":"105","author":"D\u2019Antiga","year":"2026","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.039_bib0010","doi-asserted-by":"crossref","first-page":"173.e1","DOI":"10.1016\/j.jtct.2025.10.032","article-title":"Comparative analysis of lymphodepletion regimens in CART-19 treatment for relapsed\/refractory diffuse large B cell lymphoma","volume":"32","author":"Christodoulou","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.039_bib0011","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bjh.15722","article-title":"Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis","volume":"184","author":"Mart\u00ednez-Calle","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.039_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological malignancies","volume":"57","author":"Gafter-Gvili","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.07.039_bib0013","unstructured":"Food and Drug Administration. Bendamustine hydrochloride. 2025. https:\/\/www.fda.gov (Accessed March 20, 2026)"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.039_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.039_bib0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.07.039_bib0016","unstructured":"TriNetX, LLC. TriNetX federated health research network. 2026. https:\/\/www.trinetx.com (Accessed March 4, 2026)"},{"key":"10.1016\/j.jtct.2026.07.039_bib0018","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2023.41.16_suppl.7528","volume":"41","author":"Frigault","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.039_bib0019","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/pds.5216","article-title":"Health outcomes coding trends in the US Food and Drug Administration\u2019s sentinel system during transition to International Classification of Diseases-10 coding system: a brief review","volume":"30","author":"Nam","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtct.2026.07.039_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e18605","article-title":"Immediate inpatient toxicities associated with CAR T-cell therapy: real world data from a national inpatient sample","volume":"41","author":"Singh","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:19:07Z","timestamp":1793884747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726005993"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.039","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}